



Department
of Health

2014 Pharmaceutical Price Regulation Scheme (PPRS)

Aggregate net sales and payment information — November 2017

DH ID box
Title: 2014 Pharmaceutical Price Regulation Scheme (PPRS) Aggregate net sales and payment information — November 2017
Author: Community Care/ Medicines and Pharmacy/Medicines Pricing and Supply / Cost Centre No. 17080
Document Purpose: Transparency
Publication date: Dec 2017
Target audience: Department of Health and the Association of the British Pharmaceutical Industry.
Contact details: michael.vidal@dh.gsi.gov.uk

You may re-use the text of this document (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government-licence/

© Crown copyright 2016

Published to gov.uk, in PDF format only.

www.gov.uk/dh

Contents

Contents 3

2014 Pharmaceutical Price Regulation Scheme (PPRS)..... 4

Aggregate net sales and payment information — November 2017 4

2014 Pharmaceutical Price Regulation Scheme (PPRS)

Aggregate net sales and payment information — November 2017

TABLE 1 — Audited annual PPRS payment sales reports: measured spend in growth calculation by calendar year

	Aggregate net sales subject to medicines bill growth calculation (measured spend)		
2013	£7,834M		
2014	£8,327M	£8,093M	
2015		£8,127M	£8,272M
2016			£8,491M

Table 1 notes

Table 1 sets out aggregate information for calendar years 2013, 2014, 2015 and 2016 reported through 2014 PPRS members' audited annual PPRS payment sales reports or best available information where the audited submissions have yet to be provided.

The information set out is the net sales subject to branded medicines bill growth calculation (measured spend).

Note: Measured spend is defined in paragraph 6.6 of the PPRS and means the spend which is controlled by the PPRS payments mechanism. It includes sales of new products.

Each column of the table contains a separate basket of companies for each growth calculation, which are dependent on the members of the scheme included in the growth calculation and ensuring that the same companies are in both the numerator and the denominator of the respective calculations.

The figures in all parts of Table 1 do not take into account the treatment of the Cancer Drugs Fund (CDF) in the growth calculation following the agreement reached on the CDF between the Department and the ABPI. The effect of this is that the excluded amounts are added to the allowed spend². The amount (net of VAT) added to allowed spend following the CDF agreement is:

- Calendar year 2014 — £ 91M
- Calendar year 2015 — £107M
- Calendar year 2016 — £ 35M

TABLE 2 — Unaudited PPRS payment sales reports: measured spend in growth calculation for 2015/2016 to 2016/2017

	Aggregate net sales subject to medicines bill growth calculation (measured spend)
2015/2016	£8,424M
2016/2017	£8,862M

Table 2 notes

Table 2 sets out aggregate information for the 2015/16 to 2016/17 growth calculation. This is derived from the unaudited quarterly PPRS payment sales reports provided by members of the 2014 PPRS for the following periods

2015/2016 comprises	2016/2017 comprises
2015 Q4	2016 Q4
2016 Q1	2017 Q1
2016 Q2	2017 Q2
2016 Q3	2017 Q3

The information set out is the Net sales subject to branded medicines bill growth calculation (measured spend).

Note: The addition to the allowed spend follows the method set out in the revised addendum to the PPRS at <https://www.gov.uk/government/publications/pharmaceutical-price-regulation-scheme-2014>. The figures for 2014, 2015 and 2016 are final. The figures for other years will depend on the latest information on CDF spend.

The figures in Table 2 do not take into account the treatment of the CDF in the growth calculation following the agreement reached on the CDF between the Department and the ABPI. The effect of this is that the excluded amounts are added to the Allowed Spend.

TABLE 3 — PPRS payment sales reports: net sales covered by the PPRS payment and resulting PPRS payments

	Aggregate net sales covered by the PPRS payment	Resulting aggregate PPRS payments Column 2
--	---	---

	Column 1	
2013	£7,901M	N/A
2014	£8,338M	£311M
2015	£8,164M	£845M
2016	£8,000M	£623M
2017 Q1	£1,998M	£95M
2017 Q2	£2,000M	£95M
2017 Q3	£2,026M	£96M

Table 3 notes

Table 3, which is derived from audited annual PPRS payment sales reports and unaudited quarterly PPRS payment sales reports provided by members of the 2014 PPRS, sets out aggregate annual audited and unaudited quarterly information showing net sales covered by the PPRS payment and PPRS payments received by the Department for the following periods:

<u>Audited</u>	<u>Unaudited</u>
2013	2017 Q1
2014	2017 Q2
2015	2017 Q3
2016	

There are two columns of information:

Column 1 — Aggregate net sales covered by the PPRS payment;

Column 2 — Resulting aggregate PPRS payments due for the respective periods.

Note: Sales covered by the PPRS payment is defined at paragraph 6.7 of the PPRS. The percentage payment applies to these sales, which exclude sales of new products. Sales of new products are included in the calculation of the overall sum to be repaid across all member companies. However, products with a new active substance designation which were introduced after 31 December 2013 are excluded from the sales used to calculate the payment by each company.

Note: Sales covered by the PPRS payment will include sales from submissions that companies have made in accordance with the rules for companies joining the PPRS payment mechanism after September 2014.

General notes

Note 1: The information in all tables is that held on the Department of Health's PPRS operations database at 21 November 2017.

Note 2: All tables are subject to future correction where errors are discovered or where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 6.24-6.30 and 6.37-6.40 of the PPRS.